logo

Azurrx Biopharma, Inc. (AZRX)



Trade AZRX now with
  Date
  Headline
10/10/2019 7:36:33 AM AzurRx BioPharma Names James Sapirstein CEO
9/25/2019 8:16:17 AM AzurRx BioPharma Announces Positive Results From Phase 2 Trial With MS1819 In Cystic Fibrosis Patients
3/18/2019 7:50:48 AM ZurRx BioPharma Announces Presentation On Positive Phase II Data In MS1819-SD At 2019 Digestive Disease Week Conference
2/20/2019 7:48:40 AM AzurRx BioPharma Announces First Patients Dosed In Phase II OPTION Clinical Trial
12/19/2018 8:07:59 AM AzurRx BioPharma Begins Phase II OPTION Study To Investigate MS1819-SD
12/12/2018 8:08:20 AM AzurRx BioPharma To Buy Payment Rights To Lead Drug Candidate MS1819-SD From Protea Biosciences Group
10/16/2018 7:34:10 AM AzurRx BioPharma Announces FDA Acceptance Of IND Application For Phase 2 Clinical Trial Of MS1819-SD
6/29/2018 8:31:36 AM AzurRx BioPharma Announces Phase IIa Trial Of MS1819-SD In Exocrine Pancreatic Insufficiency
5/1/2018 9:11:30 AM AzurRx BioPharma Prices Underwritten Public Offering Of 4.16 Mln Shares At Offering Price Of $2.50/shr
5/1/2018 9:11:18 AM AzurRx BioPharma Prices Public Offering Of 4.16 Mln Shares At $2.50 Per Share
4/23/2018 8:54:06 AM AzurRx, Mayoly-Spindler Announce Addl Positive Interim Data For MS1819-SD Phase II In Exocrine Pancreatic Insufficiency
4/18/2018 7:46:12 AM AzurRx BioPharma Announces Positive Preclinical Results For AZX1103
2/12/2018 8:15:55 AM AzurRx BioPharma Reports Enrollment Of Three New Patients For Its Phase IIa Study Of MS1819-SD
1/18/2018 8:09:48 AM AzurRx Announces Receipt Of Required Approvals To Add French Clinical Site For Its Phase IIa Study Of MS1819-SD
  
 
>